Pulmonary fibrosis drug 'Ofev' under consideration for reimb

By Lee, Tak-Sun | translator Hong, Ji Yeon

25.01.17 05:21:40

가나다라 0

The DREC on January 9 gave a drug appropriateness decision for the second and third indications, while excluding the first indication

Drugs from Yungjin Pharm and Daewoong have been approved as formulation change drugs…following reimbursement approval of Ofev, generic companies are projected to aim for estimated course

As 'Ofev Soft cap (nintedanib),' a treatment for pulmonary fibrosis, has been approved for reimbursement appropriateness, latecomer drugs are projected to enter the market quickly.

Following the expiration of Ofev's usage patent, latecomer companies are anticipated to prepare for launching their drugs.

According to industry sources on January 16, Daewoong's "Ofevvia tab 150 mg,' containing the same active ingredient as Ofev Soft Cap, was approved by the Ministry of Food and Drug Safety (MFDS).

Last month, Yungjin Pharm's 'Nintebro Tab 150mg,' containing the same active ingredient, was approved. These companies aim to join the market early by changing the capsule formation o

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)